Abstract | PURPOSE: Single-agent PF-3512676 (agatolimod), a Toll-like receptor 9 agonist, was examined in an open-label, single-arm, multicenter phase I/II study to determine its maximum tolerated dose (MTD), safety profile, antitumor activity, pharmacokinetics, and immunologic effects in patients with advanced metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS:
PF-3512676 was administered subcutaneously weekly for up to 24 weeks to 39 adults with stage IV RCC. Patients were excluded if they had received previous therapy other than surgery. Phase I dose escalation began at 0.08 mg/kg, with phase II expansion to 20 patients to estimate objective response rates at 0.16 mg/kg. Doses were subsequently escalated to 0.81 mg/kg according to the phase I design. RESULTS: An MTD was not reached. One patient who received 0.54 mg/kg had dose-limiting toxicities (grade 3 nonhematologic adverse events [AEs], including anorexia). The most commonly reported AEs were flu-like symptoms and local injection-site reactions of mild-to-moderate severity. The most commonly reported serious AE was grade 3 fatigue in 4 patients (10%). Grade 4 AEs included anemia, exacerbated dyspnea, and polyarthralgia in 1 patient each. Two patients (5%), 1 each in the 0.16-mg/kg and 0.54-mg/kg cohorts, achieved a partial response. Both responses were durable (35 and 40 months). CONCLUSION: This was the first study to examine PF-3512676 safety and antitumor activity in patients with advanced RCC. Single-agent treatment was tolerable. At the doses tested, PF-3512676 had modest antitumor activity. Additional studies in combination with other agents or at higher monotherapy doses might be warranted.
|
Authors | John A Thompson, Timothy Kuzel, Beverly J Drucker, Walter J Urba, Ronald M Bukowski |
Journal | Clinical genitourinary cancer
(Clin Genitourin Cancer)
Vol. 7
Issue 3
Pg. E58-65
(Oct 2009)
ISSN: 1938-0682 [Electronic] United States |
PMID | 19815483
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Oligodeoxyribonucleotides
- ProMune
- TLR9 protein, human
- Toll-Like Receptor 9
|
Topics |
- Adult
- Antineoplastic Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Carcinoma, Renal Cell
(drug therapy, pathology)
- Chemotherapy, Adjuvant
- Female
- Humans
- Kidney Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Oligodeoxyribonucleotides
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Toll-Like Receptor 9
(agonists)
- Treatment Outcome
|